CORV traded down $0.28 during trading on Thursday, reaching $1.57. The stock had a trading volume of 690,748 shares, compared to its average volume of 84,915. The stock has a market capitalization of $75.89 million, a PE ratio of -1.76 and a beta of 0.44. The company has a current ratio of 2.80, a quick ratio of 2.42 and a debt-to-equity ratio of 7.21. Correvio Pharma has a one year low of $1.55 and a one year high of $5.24. The firm’s 50-day moving average is $2.08.
Correvio Pharma (NASDAQ:CORV) last released its earnings results on Wednesday, May 8th. The company reported ($0.23) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.04). The firm had revenue of $7.25 million during the quarter, compared to the consensus estimate of $7.91 million. Correvio Pharma had a negative net margin of 58.25% and a negative return on equity of 375.42%. On average, analysts forecast that Correvio Pharma will post -0.75 earnings per share for the current fiscal year.
About Correvio Pharma
Correvio Pharma Corp. operates as a pharmaceutical company, which engages in the provision of development and commercialization of medical products. It operates through the Europe and Rest of the World geographical segments. The firm focuses on cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease.
Further Reading: What is quantitative easing?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Correvio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Correvio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.